Rebecca N Jerome1, Jill M Pulley1, Nila A Sathe2,3, Shanthi Krishnaswami2, Alyssa B Dickerson1, Katherine J Worley1,2, Consuelo H Wilkins4. 1. Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, TN. 2. Vanderbilt Evidence-Based Practice Center, Institute for Medicine and Public Health, Vanderbilt University Medical Center, Nashville, TN. 3. Vanderbilt Department of Health Policy, Institute for Medicine and Public Health, Vanderbilt University Medical Center, Nashville, TN. 4. Department of Medicine, Vanderbilt University Medical Center and Department of Internal Medicine, Meharry Medical College, Nashville, TN.
Abstract
Purpose: Management of schizophrenia among Blacks in the United States is affected by persistent disparities. This review explored response to atypical antipsychotics among Blacks compared with other groups to assess systematic variation that may contribute to disparities. Methods: We conducted a quasi-systematic review of studies reporting response to atypical antipsychotics among Blacks compared with other groups, including effects of genetic variation. Results: Of 48 identified research articles, 29 assessed differences in outcomes without inclusion of genetic variation and 20 explored effects of genetic variation; of note: one article included both types of data. Analysis of the 29 papers with clinical outcomes only suggests that while data on efficacy and risk of movement disorders were heterogeneous, findings indicate increased risk of metabolic effects and neutropenia among Blacks. Of the 20 articles exploring effects of genetic variation, allelic or genotypic variations involving several genes were associated with altered efficacy or safety among Blacks but not Whites, including risk of decreased response involving variation in DRD4 and DRD1, and improved efficacy associated with variants in DRD2, COMT, and RGS4. Others showed significant improvement in treatment response only among Whites, including variation in DTNBP1, DRD4, and GNB3. Conclusions: The current analysis can help tailor management among Blacks using an atypical antipsychotic. Heterogeneity in genetic variation effects and response allele frequency suggests that pharmacogenetics approaches for atypical antipsychotics will need to explicitly incorporate race and ethnicity.
Purpose: Management of schizophrenia among Blacks in the United States is affected by persistent disparities. This review explored response to atypical antipsychotics among Blacks compared with other groups to assess systematic variation that may contribute to disparities. Methods: We conducted a quasi-systematic review of studies reporting response to atypical antipsychotics among Blacks compared with other groups, including effects of genetic variation. Results: Of 48 identified research articles, 29 assessed differences in outcomes without inclusion of genetic variation and 20 explored effects of genetic variation; of note: one article included both types of data. Analysis of the 29 papers with clinical outcomes only suggests that while data on efficacy and risk of movement disorders were heterogeneous, findings indicate increased risk of metabolic effects and neutropenia among Blacks. Of the 20 articles exploring effects of genetic variation, allelic or genotypic variations involving several genes were associated with altered efficacy or safety among Blacks but not Whites, including risk of decreased response involving variation in DRD4 and DRD1, and improved efficacy associated with variants in DRD2, COMT, and RGS4. Others showed significant improvement in treatment response only among Whites, including variation in DTNBP1, DRD4, and GNB3. Conclusions: The current analysis can help tailor management among Blacks using an atypical antipsychotic. Heterogeneity in genetic variation effects and response allele frequency suggests that pharmacogenetics approaches for atypical antipsychotics will need to explicitly incorporate race and ethnicity.
Authors: D J Müller; C C Zai; M Sicard; E Remington; R P Souza; A K Tiwari; R Hwang; O Likhodi; S Shaikh; N Freeman; T Arenovich; A Heinz; H Y Meltzer; J A Lieberman; J L Kennedy Journal: Pharmacogenomics J Date: 2010-08-17 Impact factor: 3.550
Authors: Jose de Leon; Francisco J Diaz; Richard C Josiassen; Thomas B Cooper; George M Simpson Journal: J Clin Psychopharmacol Date: 2007-02 Impact factor: 3.153
Authors: Deanna L Kelly; Julie Kreyenbuhl; Lisa Dixon; Raymond C Love; Deborah Medoff; Robert R Conley Journal: Schizophr Bull Date: 2006-12-14 Impact factor: 9.306
Authors: Rudi Hwang; Renan P Souza; Arun K Tiwari; Clement C Zai; Daniel J Müller; Steven G Potkin; Jeffrey A Lieberman; Herbert Y Meltze; James L Kennedy Journal: Pharmacogenomics Date: 2011-02 Impact factor: 2.533
Authors: John M Kane; Timothy Peters-Strickland; Ross A Baker; Peter Hertel; Anna Eramo; Na Jin; Pamela P Perry; Michelle Gara; Robert D McQuade; William H Carson; Raymond Sanchez Journal: J Clin Psychiatry Date: 2014-11 Impact factor: 4.384
Authors: Drew H Barzman; Melissa P DelBello; Jacob J Forrester; Paul E Keck; Stephen M Strakowski Journal: J Child Adolesc Psychopharmacol Date: 2007-08 Impact factor: 2.576
Authors: Monkol Lek; Konrad J Karczewski; Eric V Minikel; Kaitlin E Samocha; Eric Banks; Timothy Fennell; Anne H O'Donnell-Luria; James S Ware; Andrew J Hill; Beryl B Cummings; Taru Tukiainen; Daniel P Birnbaum; Jack A Kosmicki; Laramie E Duncan; Karol Estrada; Fengmei Zhao; James Zou; Emma Pierce-Hoffman; Joanne Berghout; David N Cooper; Nicole Deflaux; Mark DePristo; Ron Do; Jason Flannick; Menachem Fromer; Laura Gauthier; Jackie Goldstein; Namrata Gupta; Daniel Howrigan; Adam Kiezun; Mitja I Kurki; Ami Levy Moonshine; Pradeep Natarajan; Lorena Orozco; Gina M Peloso; Ryan Poplin; Manuel A Rivas; Valentin Ruano-Rubio; Samuel A Rose; Douglas M Ruderfer; Khalid Shakir; Peter D Stenson; Christine Stevens; Brett P Thomas; Grace Tiao; Maria T Tusie-Luna; Ben Weisburd; Hong-Hee Won; Dongmei Yu; David M Altshuler; Diego Ardissino; Michael Boehnke; John Danesh; Stacey Donnelly; Roberto Elosua; Jose C Florez; Stacey B Gabriel; Gad Getz; Stephen J Glatt; Christina M Hultman; Sekar Kathiresan; Markku Laakso; Steven McCarroll; Mark I McCarthy; Dermot McGovern; Ruth McPherson; Benjamin M Neale; Aarno Palotie; Shaun M Purcell; Danish Saleheen; Jeremiah M Scharf; Pamela Sklar; Patrick F Sullivan; Jaakko Tuomilehto; Ming T Tsuang; Hugh C Watkins; James G Wilson; Mark J Daly; Daniel G MacArthur Journal: Nature Date: 2016-08-18 Impact factor: 49.962
Authors: Rebecca N Jerome; Jill M Pulley; Nila A Sathe; Shanthi Krishnaswami; Alyssa B Dickerson; Katherine J Worley; Maria F Lima; Consuelo H Wilkins Journal: J Natl Med Assoc Date: 2020-07-28 Impact factor: 1.798